1 Qian M, Wu D, Wang E, et al. Development and promotion in translational medicine: perspectives from 2012 sinoamerican symposium on clinical and translational medicine. Clin Transl Med 2012; 1: 25.
2 Collins F. The bridge between lab and clinic. Interview by Meredith Wadman. Nature 2010; 468: 877.
3 Moss S. Translational research: Don’t neglect basic science. Nature 2008; 454: 274.
4 Lehmann CU, Altuwaijri MM, Li YC, et al. Translational research in medical informatics or from theory to practice.
A call for an applied informatics journal. Methods Inf Med2008; 47: 1-3.
5 Marincola FM, Sheikh JI. A road map to Translational Medicine in Qatar and a model for the world. J Transl Med 2012; 10: 177.
6 Brander C, Ferrone S, Marineola F. Rewarding patientdirected research: Excellence in translational medicine award. J Transl Med 2006; 4: 19.
7 Albani S, Prakken B. The advancement of translational medicine-from regional challenges to global solutions. Nat Med 2009; 15: 1006-9.
8 Carpenter S. Science careers. Carving a career in translational research. Science 2007; 317: 966-7.
9 Carlson RW; NCCN Breast Cancer Panel. Ten years of progress against breast cancer: a partnership of basic and clinical/translational science. J Natl Compr Canc Netw 2013; 11: 132-6.
10 Albani S, Colomb J, Prakken B. Translational medicine 2.0: From clinical diagnosis based to molecular-targeted therapies in the era of globalization. Clin Pharmacol Ther 2010; 87: 642-5.
11 Mathew JP, Taylor BS, Bader GD, et al. From bytes to bedside: data integration and computational biology for translational cancer research. PLoS Comput Biol 2007; 3: e12.
12 Payne PR, Embi PJ, Sen CK. Translational informatics: enabling high-throughput research paradigms. Physiol Genomics 2009; 39: 131-40.
13 Zhou J, Wu D, Liu X, et al. Translational medicine as a permanent glue and force of clinical medicine and public health: perspectives (1) from 2012 Sino-American symposium on clinical and translational medicine. Clin Transl Med 2012; 1: 21.
14 Reed JC, White EL. NIH: translation centre bridges a gap. Nature 2011; 474: 161.
15 Giordano J, Garcia MK, Strickland G. Integrating Chinese traditional medicine into a U.S. public health paradigm. J Altern Complement Med 2004; 10: 706-10.
16 Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010; 69: 1423-9.
17 Cuende N, Izeta A. Clinical translation of stem cell therapies: Clinical translation of stem cell therapies: a bridgeable gap. Stem Cell 2010; 6: 508-12.
18 Volponi AA, PangY, Sharpe PT. Stem cell-based biological tooth repair and regeneration. Trends Cell Biol 2010; 20: 715-22.
19 Chen FM, Jin Y. Periodontal tissue engineering and regeneration: Current approaches and expanding opportunities. Tissue Eng Part B Rev 2010; 16: 219-55.
20 Kim JY, Xin X, Moioli EK, et al. Regeneration of dentalpulp-like tissue by chemotaxis-induced cell homing. Tissue Eng Part A 2010; 16: 3023-31.
21 Kim K, Lee CH, Kim BK, et al. Anatomically shaped tooth and periodontal regeneration by cell homing. J Dent Res 2010; 89: 842-7.
22 Chen FM, Zhang J, Zhang M, et al. A review on endogenous regenerative technology in periodontal regenerative medicine. Biomaterials 2010; 31: 7892-927.
23 Anitua E, Sánchez M, Orive G. Potential of endogenous regenerative technology for in situ regenerative medicine. Adv Drug Deliv Rev 20l0; 62: 741-52.
24 Abassi Z, Winaver J, Feuerstein GZ. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. Biochem Pharmacol 2009; 78: 933-40.
25 Kris MG. Foreword; challenging the ‘one-size-fits-all’approach of chemotherapy and radiotherapy for patients with non-small cell lung cancer. Lung Cancer 2008; 60: S1-2.
26 Decker T, Fischer G, Bücke W, et al. Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer.
27 Cozzi J, Fraichard A, Thiam K. Use of genetically modified rat models for translational medicine. Drug Discov Today 2008; 13: 488-94.
28 Decker T, Fischer G, Bücke W, et al. Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. J Cancer Res Clin Oncol 2012; 138: 1945-50.
29 Weiss VL, Lee TH, Song H, et al. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One 2012; 7: e31962.
30 Pestrin M, Bessi S, Puglisi F, et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 2012; 134: 283-9.
31 Johnson MO, Subak LL, Brown JS, et al. An innovative program to train health sciences researchers to be effective clinical and translational research mentors. Acad Med 2010; 85: 484-9.